Allurion Technologies’ (ALUR) Neutral Rating Reaffirmed at Chardan Capital

Chardan Capital reaffirmed their neutral rating on shares of Allurion Technologies (NYSE:ALUR) in a report issued on Thursday,Benzinga reports. Chardan Capital currently has a $2.50 price target on the stock. Chardan Capital also issued estimates for Allurion Technologies’ FY2025 earnings at ($4.39) EPS.

Separately, Roth Mkm reaffirmed a “buy” rating and issued a $16.00 price target on shares of Allurion Technologies in a research report on Friday, March 21st.

Allurion Technologies Stock Performance

Shares of ALUR opened at $3.25 on Thursday. Allurion Technologies has a fifty-two week low of $2.15 and a fifty-two week high of $98.75. The firm’s 50-day simple moving average is $4.01 and its two-hundred day simple moving average is $9.84. The stock has a market cap of $15.57 million, a PE ratio of -0.27 and a beta of -0.59.

Allurion Technologies (NYSE:ALUR) last posted its quarterly earnings results on Wednesday, March 26th. The company reported ($7.00) earnings per share for the quarter, missing the consensus estimate of ($5.00) by ($2.00). The company had revenue of $5.59 million during the quarter, compared to the consensus estimate of $5.60 million. Equities research analysts predict that Allurion Technologies will post -9.96 EPS for the current year.

Institutional Trading of Allurion Technologies

An institutional investor recently raised its position in Allurion Technologies stock. Geode Capital Management LLC lifted its holdings in shares of Allurion Technologies Inc. (NYSE:ALUR) by 40.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 516,330 shares of the company’s stock after buying an additional 149,484 shares during the period. Geode Capital Management LLC owned approximately 0.80% of Allurion Technologies worth $317,000 at the end of the most recent reporting period. 21.39% of the stock is currently owned by institutional investors and hedge funds.

Allurion Technologies Company Profile

Allurion Technologies Inc focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite.